Drugs / pilsicainide
pilsicainide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT07447297 | Jan 2024 → Dec 2027 expected | atrial fibrillation, atrial flutter | Samsung Medical Center | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT01775891 Comparator | Jul 2012 → Jul 2015 | paroxysmal atrial fibrillation | Korea University | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pilsicainide | “flecainide, propafenone, pilsicainide, sotalol, amiodarone, dronedarone and so on” NCT07447297 ↗ |
| Known as | Pilsicainida | ChEMBL registry synonym — accepted as the source's own label CHEMBL163238 ↗ |
| Known as | Pilsicainide (Sunrhythm) Daiichi Sankyo | “Pilsicainide (Sunrhythm®) Daiichi Sankyo” NCT01775891 ↗ |
| Action | Inhibit | “which has a pure sodium channel blocking action” NCT01775891 ↗ |
| Modality | Small molecule | — CHEMBL163238 ↗ |
| Route | Oral | “The dose of pilsicainide will be 50mg tid PO.” NCT01775891 ↗ |